# Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma

> **NCT06657157** · — · RECRUITING · sponsor: **Comprehensive Cancer Center Munich (CCCM)** · enrollment: 80 (estimated)

## Conditions studied

- Urothelial Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06657157
- **Lead sponsor:** Comprehensive Cancer Center Munich (CCCM)
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-22
- **Primary completion:** 2026-12
- **Final completion:** 2027-02
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06657157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06657157, "Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06657157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*